logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Precious Metals
Gold Price TodayGold Price TodayNew
Silver Price TodaySilver Price TodayNew
Platinum Price TodayPlatinum Price TodayNew
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Vineet Laboratories Ltd

Vineet Laboratories

Small Cap•IPO 2021
Current Price
₹29.51
0.04 (0.14%)Updated
NSE :VINEETLAB
BSE :543298
Sector :Pharmaceuticals
Today's Range
29.32
₹29.51
indicator
30.21
52 Week Range
52W Low₹26.51
52W High₹49.99
₹29.51
indicator
Downside11.32%
Upside69.40%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹60.3 Cr
Market Cap
Total market value of company
P/E Ratio
-
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
2.19
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹-20.47
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
-66.72%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
-28.00%
ROCE
Return on Capital Employed. >15% is good
Net Margin
-15.76%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
-%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
-68.80%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
59.20%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
2.74
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹15.84
Book Value
Net asset value per share
Dividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
15.90%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

0 points

    Weaknesses

    5 points
    • •Severe unprofitability with ROE -89.50% and ROCE -28.00%.
    • •Quarterly sales plummeted -68.80%, indicating significant revenue contraction.

    Opportunities

    4 points
    • •Pharmaceutical sector offers growth from increasing healthcare demand and advancements.
    • •Diversification into new products or markets could capture emerging needs.

    Threats

    5 points
    • •Highly competitive pharmaceutical industry threatens market share and pricing power.
    • •Stringent regulatory changes could increase operational costs and impact approvals.

    Segment-wise Financial Analysis

    Fetching Financials...
    Fetching Balance Sheet...
    Fetching Cash Flow...

    Shareholding Pattern

    Loading shareholding data...

    Company Insider Trading Activity

    Recent Insider Transactions

    Insider NameTransaction DateFiling DateTotal SharesChangePriceAction
    Alluri Srinivasa Raju
    		16 May 202517 May 20251.55 L
    25,000
    		₹32.32SELL
    Alluri Srinivasa Raju
    		16 May 202517 May 20251.80 L
    25,000
    		₹32.3SELL
    Alluri Srinivasa Raju
    		15 May 202517 May 20252.05 L
    25,000
    		₹30.62SELL
    Alluri Srinivasa Raju
    		15 May 202517 May 20252.30 L
    25,000
    		₹30.55SELL
    VENKATA RAMAGADDAM
    		26 May 202529 May 20254.78 L
    70,000
    		₹32.1SELL

    Corporate Action

    Company Announcements

    Technical Analysis & Indicators

    Standard pivot points - most widely used

    Pivot Points (CLASSIC)

    LevelPriceDistance% Change
    R4₹31.82+₹2.31+7.83%
    R3₹30.93+₹1.42+4.81%
    R2₹30.57+₹1.06+3.59%
    R1₹30.04+₹0.53+1.80%
    PIVOT₹29.680.170.58%
    CURRENT₹29.51--
    S1₹27.37-₹2.14-7.25%
    S2₹28.26-₹1.25-4.24%
    S3₹28.79-₹0.72-2.44%
    S4₹29.15-₹0.36-1.22%
    CPR Levels
    Support
    Resistance
    S4
    S3
    S2
    S1
    | CPR |
    BC: N/AP: N/ATC: N/A
    R1
    R2
    R3
    R4
    indicator
    LTP: N/A
    PDH: N/A
    PDL: N/A
    ● Market Sentiment

    is trading CPR, indicating

    ● CPR Width

    CPR is

    ● Opening Range

    Day's range: ~

    ● Price Position

    Trading Inside opening range

    Delivery Volume Analysis & Trading Activity

    Latest Volume
    0.34L
    (02 Apr 2026)
    -69.7% vs avg
    Delivery %
    34.5%
    (02 Apr 2026)
    -20.3% vs avg
    Avg Volume (20D)
    1.14L
    (04 Mar - 02 Apr)
    20-day average
    Avg Delivery %
    54.8%
    (04 Mar - 02 Apr)
    Trend ↓
    Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

    Peer Comparison & Industry Benchmarking

    Quick Compare

    Largest by Market Cap
    Sun Pharmaceutical Industries Ltd
    4.12L ₹ Cr
    Best Profit Growth
    Biofil Chemicals & Pharmaceuticals Ltd
    1318.00 %
    Highest Dividend Yield
    Sun Pharmaceutical Industries Ltd
    0.91 %

    Peer Comparison

    Company Name
    BIOFILCHEM
    Biofil Chemicals & Pharmaceuticals Ltd
    LASA
    Lasa Supergenerics Ltd
    MANGALAM
    Mangalam Drugs and Organics Ltd
    SUNPHARMA
    Sun Pharmaceutical Industries Ltd

    About

    VINEETLAB

    Vineet Laboratories Ltd

    Vineet Laboratories Limited is an Indian company specializing in the research, development, manufacturing, and sales of active pharmaceutical ingredients (APIs) and fine chemicals. Their primary focus is on supplying crucial components for the pharmaceutical industry, contributing to the production of various medications.

    A significant portion of Vineet Labs' business involves the production of intermediates for several key APIs. These intermediates are essential building blocks used in the synthesis of finished pharmaceutical products. Specific examples of APIs for which they supply intermediates include Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, and Piroctone Olanine. The company's ability to reliably produce these intermediates is vital to the supply chains of pharmaceutical manufacturers.

    Beyond APIs, Vineet Laboratories also offers a diverse range of fine chemicals and reagents. These chemicals serve a variety of purposes in research and manufacturing settings, extending their reach beyond just pharmaceutical applications. The list of fine chemicals they provide is extensive and includes compounds such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, and various other specialized reagents. This diversification broadens their customer base and enhances their market position.

    Established in 2007 and headquartered in Hyderabad, India, Vineet Laboratories has built its foundation on providing high-quality chemical products to both domestic and potentially international markets. Their success is likely linked to their expertise in chemical synthesis, quality control, and meeting the stringent demands of the pharmaceutical and research industries. The company’s commitment to research and development likely allows them to adapt to evolving market needs and introduce new products.

    COMPANY FACTS - VINEETLAB

    Registered Address

    H.No: 5-5-160, Malleswari Nilayam,, Opp.Vishnu Theatre, Chintalkunta,, LB Nagar

    Hyderabad

    TELANGANA

    IN

    Tel: 914024128833

    Website:http://vineetlabs.co.in/

    Investor Relations:http://www.vineetlabs.co.in/co-sec.html
    Company Details

    Group: Pharmaceuticals, Biotechnology & Life Sciences

    Sector: Health Care

    Industry: Pharmaceuticals

    Exchange: NATIONAL STOCK EXCHANGE OF INDIA

    0

    IPO Date: 15/06/2021

    MANAGEMENT - VINEETLAB

    Mr. Satyanarayana Bhupathiraju

    Chief Financial Officer, Whole Time Director

    Mr. Rameshkumar Bandari

    Compliance Officer, Company Secretary

    Mr. Gaddam Ramana

    Managing Director, Executive Director

    Mr. Premananda Vennapusa

    Non-Executive Director

    Mr. Dilip Acharekar

    Non-Executive Independent Director

    Mrs. Hari Priya Yerukalapudi

    Additional Non-Executive Independent Director

    Investor Questions Answered

    Vineet Laboratories Ltd (VINEETLAB) Stock FAQs

    Get answers to the most common questions about Vineet Laboratories Ltd stock price, fundamentals, financial metrics, and investment analysis

    The current share price of Vineet Laboratories Ltd (VINEETLAB) is ₹29.51. Today, the stock has gained by ₹0.04 (0.14%), trading in a range of ₹29.32 to ₹30.21. The stock opened at ₹29.52 with a trading volume of 34,369 shares.
    Vineet Laboratories Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹60.3 crores, P/E ratio of 0.00, ROE of -66.72%, and ROCE of -28.00%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
    The 52-week high price of Vineet Laboratories Ltd (VINEETLAB) is ₹49.99, while the 52-week low is ₹26.51. Currently trading at ₹29.51, the stock is 12.8% away from its 52-week low and 41.0% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
    Whether to buy Vineet Laboratories Ltd stock at ₹29.51 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of N/A. Today's performance shows a gain of 0.14%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
    Vineet Laboratories Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹29.51, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
    Vineet Laboratories Ltd's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: N/A, ROE: -66.72%, ROCE: -28.00%, Dividend Yield: 0.00%, EPS: ₹-20.47, Book Value: ₹15.84, Debt-to-Equity: 2.74, and Current Ratio: N/A. The company's market cap stands at ₹60.3 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
    Vineet Laboratories Ltd stock opened at ₹29.52 and is currently trading at ₹29.51, showing a gain of ₹0.04 (0.14%). The intraday high is ₹30.21 and low is ₹29.32. The trading volume stands at 34,369 shares, indicating moderate market participation today.
    Vineet Laboratories Ltd has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹-20.47, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
    Vineet Laboratories Ltd has a market capitalization of ₹60.3 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹29.51) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
    Vineet Laboratories Ltd has a book value of ₹15.84 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹29.51, which is 86.3% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
    Vineet Laboratories Ltd has a Return on Equity (ROE) of -66.72% and Return on Capital Employed (ROCE) of -28.00%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
    Vineet Laboratories Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
    Vineet Laboratories Ltd has a debt-to-equity ratio of 2.74, which measures the company's financial leverage by comparing total debt to shareholders' equity. A ratio above 2 indicates high leverage and potentially higher financial risk. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
    Vineet Laboratories Ltd has an Earnings Per Share (EPS) of ₹-20.47, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹29.51 and P/E ratio of 0.00, investors are paying 0.00 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
    Vineet Laboratories Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
    Vineet Laboratories Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
    To analyze Vineet Laboratories Ltd stock, consider: 1) Fundamental Analysis - Review P/E (0.00), ROE (-66.72%), debt-to-equity (2.74), and growth rates. 2) Technical Analysis - Check 52-week range (₹26.51 - ₹49.99), moving averages, and chart patterns. 3) Valuation - Compare current price (₹29.51) with book value (₹15.84) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
    The face value (or par value) of Vineet Laboratories Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹29.51 is 195x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
    Investing in Vineet Laboratories Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹26.51 - ₹49.99). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 2.74 indicates leverage. 4) Liquidity Risk - Based on trading volume of 34,369 shares. 5) Valuation Risk - P/E of 0.00 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
    Vineet Laboratories Ltd operates in the industry with key metrics: P/E ratio of 0.00, ROE of -66.72%, market cap of ₹60.3 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 2.74), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
    Target prices for Vineet Laboratories Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹29.51, with a 52-week range of ₹26.51 to ₹49.99. Based on fundamentals like P/E (0.00), ROE (-66.72%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
    Consider selling Vineet Laboratories Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹29.51. 2) Fundamental Deterioration - Declining ROE (currently -66.72%), increasing debt (D/E: 2.74), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
    Tax implications for Vineet Laboratories Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.